Our results provide the first mechanistic concept of aberrant YAP1 activation in MLS and may be of therapeutic relevance, particularly in advanced-stage tumors, which are associated with a high prevalence of IGF-IR expression and activating mutations in the PI3K/AKT axis [13]. This evidence concerns the gene YAP1 and McLeod neuroacanthocytosis syndrome.